The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up

Diane M. Harper, Pekka Nieminen, Gilbert Donders, Mark H. Einstein, Francisco Garcia, Warner K. Huh, Mark H. Stoler, Katerina Glavini, Gemma Attley, Jean Marc Limacher, Berangere Bastien, Elizabeth Calleja

Research output: Contribution to journalComment/debatepeer-review

Abstract

On a global scale, cervical cancer comprises approximately 80% of human papillomavirus (HPV)-associated cancers. These cancers are most often treated surgically, and despite a high surgical success and vaccine prevention rate; there exists a need for nonsurgical, nonablative techniques to treat HPV-associated cancers.

Original languageAmerican English
Pages (from-to)529-530
Number of pages2
JournalObstetrical and Gynecological Survey
Volume74
Issue number9
DOIs
StatePublished - Sep 1 2019
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'The Efficacy and Safety of Tipapkinogen Sovacivec Therapeutic HPV Vaccine in Cervical Intraepithelial Neoplasia Grades 2 and 3: Randomized Controlled Phase II Trial with 2.5 Years of Follow-up'. Together they form a unique fingerprint.

Cite this